Source URL: https://medicines.health.europa.eu/veterinary/en/600000060356

Nobivac Respira Bb vet. suspension for injection for dogs

Authorised

• Bordetella bronchiseptica, strain Bb7 92932, fimbriae

Product identification

Medicine name:

Nobivac Respira Bb vet. suspension for injection for dogs

Nobivac Respira Bb

Active substance:

Bordetella bronchiseptica, strain Bb7 92932, fimbriae

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Bordetella bronchiseptica, strain Bb7 92932, fimbriae 88.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes: QI07AB03
Legal status of supply: Veterinary medicinal product subject to veterinary prescription
Authorisation status: Valid
Authorised in: Germany
Available in: Germany
Package description: Available only in <u>Danish</u>
Additional information
Entitlement type: Marketing Authorisation
Legal basis of product authorisation: Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder: Intervet Deutschland GmbH
Marketing authorisation date: 14/08/2020
Manufacturing sites for batch release: Intervet International B.V.
Responsible authority: Paul-Ehrlich-Institut
Authorisation number: PEI.V.12016.01.1

14/08/2020
Reference member state: Denmark
Procedure number: DK/V/0123/002
Concerned member states: Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
PI.pdf

Date of authorisation status change: